Black box warn­ing? No wor­ries, Valeant bills Siliq as the ‘low-cost’ pso­ri­a­sis al­ter­na­tive to ri­vals from No­var­tis, Eli Lil­ly

Valeant knew it wasn’t get­ting the best new in­jectable bi­o­log­ic for pso­ri­a­sis when it went bot­tom-fish­ing at As­traZeneca and picked up bro­dalum­ab for $270 mil­lion in pre-launch cash and mile­stones. And now that it has the FDA’s ap­proval to sell the drug as Siliq, Valeant is aim­ing at a pair of ma­jor league ri­vals by pric­ing at a slight­ly low­er list price.

Valeant’s Pa­tient Ac­cess and Pric­ing Com­mit­tee — a re­cent cre­ation of their cri­sis me­di­a­tion ef­forts in the wake of a lin­ger­ing price goug­ing scan­dal — set the pub­lic price of Siliq at $3,500 a month ($42,000/year).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER